lusduna nexvue

**Lusduna Nexvue** is a long-acting, recombinant human insulin analogue (insulin glargine) designed as a follow-on biologic (“biosimilar”) referencing Lantus (insulin glargine) for once-daily subcutaneous injection. It is indicated for the treatment of diabetes mellitus (both type 1 and type 2) in adults, adolescents, and children aged 2 years and older. The mechanism of action involves stimulating peripheral glucose uptake and inhibiting hepatic glucose production, thereby lowering blood glucose. Lusduna Nexvue has a prolonged duration of action due to its unique amino acid modifications, leading to slow absorption and consistent basal insulin levels. Developed by Merck, with funding/support from Samsung Bioepis, it underwent regulatory review in both the EU (approved but withdrawn) and the US (tentative approval, final approval pending patent litigation with Sanofi, the sponsor of Lantus)[1][2][3][4][5][6][7][8][9][10][12].

Brand names

Lusduna Nexvue

Other names

insulin glargine (recombinant)